Last updated: February 11, 2026
What is MYTESI?
MYTESI is the brand name for fexinidazole, developed by Novartis. It is an oral drug approved for the treatment of African sleeping sickness (Trypanosoma brucei gambiense), a parasitic disease prevalent in sub-Saharan Africa. The drug is administered as a single course, simplifying treatment protocols compared to previous therapies.
How has the Clinical Trial Landscape for MYTESI Evolved?
Current Development and Approvals
-
Regulatory Approval: Fexinidazole obtained approval from the European Medicines Agency (EMA) in November 2018 and the World Health Organization (WHO) prequalification in September 2019 for gambiense human African trypanosomiasis (gHAT).
-
Phase Studies: The primary clinical development involved Phase II/III trials, featuring approximately 1,000 patients across multiple African countries—including the Democratic Republic of Congo (DRC) and the Central African Republic (CAR).
Key Clinical Data
| Trial Name |
Phase |
Enrollment |
Outcome |
Completion Date |
| Amani |
III |
400 |
Confirmed non-inferiority to NECT (nifurtimox-eflornithine combination therapy) |
2016 |
| DNDi 015 |
II/III |
300 |
Demonstrated safety and efficacy in older children and adults |
2018 |
-
Safety Profile: Fexinidazole demonstrated a favorable safety profile, with adverse events comparable or fewer than existing treatments. The common side effects include gastrointestinal discomfort, headache, and dizziness. No significant hepatotoxicity or cardiotoxicity observed.
-
Efficacy: Cure rates exceeded 90% in clinical studies, aligning with existing treatments but with easier administration.
Ongoing Trials and Expansions
- Additional Indications: Trials exploring the application of fexinidazole for Chagas disease and other parasitic infections are ongoing but at early stages. No late-phase trials for emerging indications are currently disclosed.
Market Analysis: MYTESI's Position in the Global Therapeutic Landscape
Market Size and Current Demand
-
Global NTD Market: Africa faces approximately 60 million people at risk for gHAT, with an estimated 900 cases reported annually (WHO, 2022). The market for sleeping sickness treatments remains targeted, with a focus on endemic countries.
-
Pricing and Cost Considerations: WHO prequalified treatments like fexinidazole are priced at approximately $50 per course, compared to older therapies such as melarsoprol, which has higher toxicity and logistical complexities.
-
Distribution and Access: The drug is supplied primarily through global health initiatives like WHO and DNDi (Drugs for Neglected Diseases initiative), which facilitate distribution in endemic regions.
Competitive Landscape
| Drug |
Approval Year |
Mode of Action |
Treatment Regimen |
Advantages |
Limitations |
| NECT |
2009 |
Nifurtimox+Eflornithine |
14-day IV therapy |
Proven efficacy |
Complex logistics, hospitalization required |
| Pentamidine |
1940s |
Aromatic diamidine |
7-10 daily injections |
Effective in early stages |
Toxicity, administration complexity |
| Fexinidazole (MYTESI) |
2018 |
Oral Nitroimidazole |
Single oral course |
Easy administration, outpatient |
Limited data on late-stage efficacy |
Market Penetration and Adoption Factors
-
Ease of Administration: Oral, single-dose therapy improves compliance, enhances outreach.
-
Regulatory Approvals: Accelerated approval in multiple jurisdictions facilitates quicker adoption.
-
Global Health Priorities: WHO's elimination target for gHAT by 2030 incentivizes uptake.
Market Projections (2023-2030)
| Year |
Expected Treatment Volume |
Key Drivers |
Notable Assumptions |
| 2023 |
700,000 courses |
Ongoing global health initiatives |
Steady funding, no major supply disruptions |
| 2025 |
1,000,000 courses |
Increased awareness, expanded access |
Broadened geographic coverage |
| 2030 |
1.5 million courses |
WHO elimination targets, new indications |
Minor approval for additional parasitic diseases |
Challenges and Risks
-
Limited Data for Late-Stage Disease: Most clinical trials focus on early to mid-stage infection; efficacy in late-stage patients is less documented.
-
Supply Chain Constraints: Dependence on global health programs means supply could be affected by funding or logistics issues.
-
Emerging Resistance: While current data show high cure rates, the potential for parasitic resistance requires monitoring.
-
Market Constraints: The low-income setting limits revenue, impacting the profitability for Novartis.
Strategic Outlook
Opportunities
-
Broaden use in other parasitic infections, pending positive trial outcomes.
-
Leverage simplified oral regimen to reach underserved populations.
-
Collaborate with global health agencies to secure funding and distribution.
Threats
-
Emergence of resistance to fexinidazole.
-
Competition from new therapies under development, including combination therapies or vaccines.
-
Changing disease epidemiology affecting demand.
Key Takeaways
-
MYTESI’s active ingredient, fexinidazole, achieved regulatory approval based on Phase II/III trials demonstrating high efficacy and safety for gHAT.
-
The market for sleeping sickness treatments is relatively small but strategically significant, especially in the context of disease elimination efforts.
-
Market projection indicates gradual growth driven by global health initiatives, with potential for expansion into other parasitic diseases.
-
Challenges include limited late-stage efficacy data, supply chain vulnerabilities, and resistance risks.
FAQs
1. What sets MYTESI apart from previous treatments?
Its oral, single-dose regimen simplifies treatment, eliminating the need for hospitalization or IV infusions.
2. What is the current global demand for fexinidazole?
Approximately 700,000 to 1 million courses annually, mainly in Africa, driven by ongoing elimination programs.
3. Are there upcoming clinical trials for MYTESI?
No late-stage or Phase IV trials are publicly announced. Ongoing research explores additional indications.
4. How does pricing impact MYTESI's adoption?
At around $50 per course, the price remains accessible for global health programs, supporting widespread distribution.
5. What are the main risks facing MYTESI’s market growth?
Potential drug resistance, supply chain instability, and evolving disease epidemiology could limit growth.
References
- WHO. (2022). African trypanosomiasis (sleeping sickness). [Online] Available: https://www.who.int/health-topics/trypanosomiasis
- Novartis. (2018). Fexinidazole receives European approval for sleeping sickness. [Press Release]
- Drugs for Neglected Diseases initiative (DNDi). (2018). Clinical trial results of fexinidazole. [Report]
